{
  "ticker": "RAC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971697",
  "id": "02971697",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0828",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1lkvkgrhfpk.pdf",
  "summary": "### **Race Oncology Ltd \u2013 Quarterly Activity Report (Appendix 4C) \u2013 Key Highlights**  \n\n#### **Material Financials**  \n- **Closing cash balance (30 June 2025):** $13.67m  \n- **Cash runway:** Funds expected to last through CY2026 (3.92 quarters based on current burn rate).  \n- **R&D spend (quarterly):** $3.11m (83% of total spending).  \n\n#### **Clinical & Operational Updates**  \n1. **Phase 1 Trial Progress:**  \n   - First patient safely dosed with **RC220 monotherapy** and **RC220 + doxorubicin** (no adverse events reported).  \n   - Ethics approval secured for trial expansion to **Prince of Wales & Queen Mary Hospitals (Hong Kong)** (post-quarter).  \n2. **Leadership Appointments:**  \n   - New **Chief Medical Officer (Dr. Jose Iglesias)** and **VP of Medical (Dr. Simon Fisher)** appointed.  \n3. **IP Update:**  \n   - Termination of **City of Hope license agreement** (deemed non-valuable; no impact on existing bisantrene rights).  \n\n#### **Other Material Events**  \n- **ESMO 2025 Presentation:** CEO to present RC220 data at **European Society of Medical Oncology** conference (October 2025).  \n\n**No capital raising, trading halt, or material liquidity risks disclosed.**  \n\n---  \n**Note:** Omitted non-material details (e.g., shareholder breakdowns, minor expenses).",
  "usage": {
    "prompt_tokens": 5728,
    "completion_tokens": 316,
    "total_tokens": 6044,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:35:49.590891"
}